The Mdm2 Promoter Snp285c/309g Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
Stian Knappskog,Merete Bjornslett,Line M. Myklebust,Petra E. A. Huijts,Maaike P. Vreeswijk,Hege Edvardsen,Yongli Guo,Xuemei Zhang,Ming Yang,Sanna K. Ylisaukko-oja,Pia Alhopuro,Johanna Arola,Rob A. E. M. Tollenaar,Christi J. van Asperen,Caroline Seynaeve,Vidar Staalesen,Ranjan Chrisanthar,Erik Lokkevik,Helga B. Salvesen,D. Gareth Evans,William G. Newman,Dongxin Lin,Lauri A. Aaltonen,Anne-Lise Borresen-Dale,Grethe S. Tell,Camilla Stoltenberg,Pal Romundstad,Kristian Hveem,Johan R. Lillehaug,Lars Vatten,Peter Devilee,Anne Dorum,Per E. Lonning
DOI: https://doi.org/10.1016/j.ccr.2010.12.019
IF: 50.3
2011-01-01
Cancer Cell
Abstract:MDM2 plays a key role in modulating p53 function. The MDM2 SNP309T > G promoter polymorphism enhances Sp1 binding and has been linked to cancer risk and young age at diagnosis although with conflicting evidence. We report a second MDM2 promoter polymorphism, SNP285G > C, residing on the SNP309G allele. SNP285C occurs in Caucasians only, where 7.7% (95% Cl 7.6%-7.8%) of healthy individuals carry the SNP285C/309G haplotype. In vitro analyses reveals that SNP309G enhances but SNP285C strongly reduces Sp1 promoter binding. Comparing MDM2 promoter status among different cohorts of ovarian (n = 1993) and breast (n = 1973) cancer patients versus healthy controls (n = 3646), SNP285C reduced the risk of both ovarian OR 0.74; Cl 0.58-0.94) and breast cancer (OR 0.79; CI 0.62-1.00) among SNP309G carriers.